Tiotropium as part of inhaled polytherapy: Adherence and associated health-care utilization

Respirology

Volumn 20, Issue 2, 2015, Pages 304-311

  Simon Tuval, Tzahit ^a   Maimon, Nimrod ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

adherence; chronic obstructive pulmonary disease; health care utilization; Tiotropium

Indexed keywords

BUDESONIDE; FLUTICASONE; FORMOTEROL; INDACATEROL; SALMETEROL; TIOTROPIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DELAYED RELEASE FORMULATION;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIROMETRY; THORAX RADIOGRAPHY; DELAYED RELEASE FORMULATION; ECONOMICS; HEALTH SERVICE; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UTILIZATION;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; FEMALE; HEALTH SERVICES; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; TIOTROPIUM BROMIDE;

EID: 84921488325     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12453     Document Type: Article

References (43)

1. Soriano JB, Lamprecht B,. Chronic obstructive pulmonary disease: a worldwide problem. Med. Clin. North Am. 2012; 96: 671-680.
2. National Institute of Health, National Heart, Lung, and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular, lung and blood diseases. 2012. [Accessed 6 Oct 2013.] Available from URL: http://www.nhlbi.nih.gov/files/docs/research/2012-ChartBook-508.pdf
3. van Boven JF, Vegter S, van der Molen T, Postma MJ,. COPD in the working age population: the economic impact on both patients and government. COPD 2013; 10: 629-639.
4. D'Souza AO, Shah M, Dhamane AD, Dalal AA,. Clinical and economic burden of COPD in a Medicaid population. COPD 2014; 12: 212-220.
5. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 188-207.
6. Terzano C, Conti V, Di Stefano F, Petroianni A, Ceccarelli D, Graziani E, Mariotta S, Ricci A, Vitarelli A, Puglisi G, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010; 188: 321-329.
7. Simon-Tuval T, Scharf SM, Maimon N, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A,. Determinants of elevated healthcare utilization in patients with COPD. Respir. Res. 2011; 12: 7.
8. Shaya F, El Khoury AC, Samant ND, Scharf SM,. Utilization of health care resources in a high-risk Medicaid population with Chronic Obstructive Pulmonary Disease. P&T 2006; 31: 261-268.
9. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB,. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch. Intern. Med. 2000; 160: 2653-2658.
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. [Accessed 19 Oct 2013.] Available from URL: http://www.goldcopd.org/uploads/users/files/GOLD-Report-2013Feb13.pdf
11. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD, Denberg T, Schünemann H, Wedzicha W, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155: 179-191.
12. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R,. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64: 457-464.
13. Anzueto A, Niewoehner DE, Leimer I, Ruhmkorf F, Celli BR, Decramer M, Tashkin DP,. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Respir. Med. 2013; 107: 1912-1922.
14. Zaniolo O, Iannazzo S, Pradelli L, Miravitlles M,. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur. J. Health Econ. 2012; 13: 71-80.
15. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M,. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
16. Anzueto A, Tashkin D, Menjoge S, Kesten S,. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther. 2005; 18: 75-81.
17. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S,. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143: 317-326.
18. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S,. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
19. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr,. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.
20. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ, Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.
21. Neyt M, Van Den Bruel A,. The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator. Eur. J. Health Econ. 2012; 13: 379-380.
22. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, Investigators INSPIRE. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26.
23. Good CB, Longo L,. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium. Ann. Intern. Med. 2006; 144: 147.
24. Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P,. Comparative efficacy of long-acting bronchodilators for COPD-a network meta-analysis. Respir. Res. 2013; 14: 100.
25. Karabis A, Lindner L, Mocarski M, Huisman E, Greening A,. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 405-423.
26. Makela MJ, Backer V, Hedegaard M, Larsson K,. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir. Med. 2013; 107: 1481-1490.
27. van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Vegter S,. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir. Med. 2014; 108: 103-113.
28. Laforest L, Licaj I, Devouassoux G, Hartwig S, Marvalin S, Van Ganse E,. Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease. Chron. Respir. Dis. 2013; 10: 11-18.
29. Halpern R, Baker CL, Su J, Woodruff KB, Paulose-Ram R, Porter V, Shah H,. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer. Adherence 2011; 5: 375-388.
30. Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R,. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir. Med. 2011; 105: 259-265.
31. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS,. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir. Med. 2011; 105: 435-441.
32. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM,. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir. Med. 2007; 101: 1398-1405.
33. Cramer JA, Bradley-Kennedy C, Scalera A,. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can. Respir. J. 2007; 14: 25-29.
34. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index 2014. [Accessed 8 Dec 2014.] Available from URL: http://www.whocc.no/atc-ddd-index/
35. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 1992; 45: 613-619.
36. Bourbeau J, Bartlett SJ,. Patient adherence in COPD. Thorax 2008; 63: 831-838.
37. George J, Kong DC, Thoman R, Stewart K,. Factors associated with medication nonadherence in patients with COPD. Chest 2005; 128: 3198-3204.
38. Stuart B, Loh FE, Roberto P, Miller LM,. Increasing Medicare part D enrollment in medication therapy management could improve health and lower costs. Health Aff. (Millwood) 2013; 32: 1212-1220.
39. Simoni-Wastila L, Wei YJ, Qian J, Zuckerman IH, Stuart B, Shaffer T, Dalal AA, Bryant-Comstock L,. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am. J. Geriatr. Pharmacother. 2012; 10: 201-210.
40. Nielsen R, Kankaanranta H, Bjermer L, Lange P, Arnetorp S, Hedegaard M, Stenling A, Mittmann N,. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respir. Med. 2013; 107: 1709-1721.
41. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R,. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 741-750.
42. Hanania NA,. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm. Pharmacol. Ther. 2008; 21: 540-550.
43. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 2011; 105: 930-938.